Literature DB >> 1696786

Chordomas with malignant spindle cell components. A DNA flow cytometric and immunohistochemical study with histogenetic implications.

R H Hruban1, F Traganos, V E Reuter, A G Huvos.   

Abstract

The authors studied four chordomas with malignant spindle cell components (SCs) and 12 conventional chordomas (CCs) by DNA flow cytometry using paraffin-embedded tissue. In addition, immunohistochemical stains for a variety of epithelial and mesenchymal markers were performed. The four SCs contained areas histologically identical to conventional chordomas, as well as a high-grade malignant spindle cell component. All four (100%) SCs had an aneuploid-multiploid DNA content. Of interest, the conventional chordoma areas in these tumors had DNA contents different from those containing the high-grade malignant spindle cells. In contrast, only three (27%) of the 11 conventional chordomas with analyzable histograms had an aneuploid-multiploid DNA content. Immunohistochemical studies performed on the four SCs showed the high-grade malignant spindle cells to stain strongly for vimentin and weakly for cytokeratin, S-100 protein, and epithelial membrane antigen (EMA), whereas the areas of conventional chordoma in these same neoplasms stained moderately for vimentin and S-100 protein, and strongly for cytokeratin and EMA. In two cases, the staining for EMA and cytokeratin highlighted a gradual transition between the areas of conventional chordoma and the spindle cell areas. The immunohistochemical staining pattern of the 12 conventional chordomas was similar to that seen in the conventional chordoma components of the four chordomas with malignant spindle cell components. These results suggest that: 1) aneuploidy is more common in SCs than in CCs, and 2) some SCs are multipotential neoplasms in which the neoplastic cells are capable of differentiation along both epithelial and mesenchymal pathways.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1696786      PMCID: PMC1877604     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  27 in total

1.  Chordoma.

Authors:  D C DAHLIN; C S MACCARTY
Journal:  Cancer       Date:  1952-11       Impact factor: 6.860

2.  Chordoma--report of an autopsy case with fibrosarcoma.

Authors:  H Kishikawa; K Tanaka
Journal:  Acta Pathol Jpn       Date:  1974-03

3.  Chordomas and cartilaginous tumors at the skull base.

Authors:  M J Heffelfinger; D C Dahlin; C S MacCarty; J W Beabout
Journal:  Cancer       Date:  1973-08       Impact factor: 6.860

4.  Sacrococcygeal chordoma with sarcomatous features (spindle cell metaplasia).

Authors:  T C Knechtges
Journal:  Am J Clin Pathol       Date:  1970-05       Impact factor: 2.493

5.  Unusual manifestations of chordoma. A report of two cases.

Authors:  J E Fox; J G Batsakis; L R Owano
Journal:  J Bone Joint Surg Am       Date:  1968-12       Impact factor: 5.284

6.  Chordoma. Thirty-five-year study at Memorial Hospital.

Authors:  N L Higinbotham; R F Phillips; H W Farr; H O Hustu
Journal:  Cancer       Date:  1967-11       Impact factor: 6.860

7.  Craniocervical chordomas.

Authors:  R D Harwick; A S Miller
Journal:  Am J Surg       Date:  1979-10       Impact factor: 2.565

8.  Malignant fibrous histiocytoma developing in irradiated sacral chordoma.

Authors:  J Halpern; J Kopolovic; R Catane
Journal:  Cancer       Date:  1984-06-15       Impact factor: 6.860

9.  Malignant fibrous histiocytoma arising in a recurrent chordoma. Case report and electron microscopic findings.

Authors:  M Makek; H J Leu
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1982

Review 10.  Chordoma. A clinicopathologic study of metastasis.

Authors:  P W Chambers; C P Schwinn
Journal:  Am J Clin Pathol       Date:  1979-11       Impact factor: 2.493

View more
  11 in total

1.  Pathobiology of selected tumors of the base of the skull.

Authors:  L Barnes
Journal:  Skull Base Surg       Date:  1991

Review 2.  Spinal chordomas dedifferentiated to osteosarcoma: a report of two cases and a literature review.

Authors:  Satoshi Kato; Alessandro Gasbarrini; Riccardo Ghermandi; Marco Gambarotti; Stefano Bandiera
Journal:  Eur Spine J       Date:  2016-04-06       Impact factor: 3.134

Review 3.  The biology and pathology of selected skull base tumors.

Authors:  L Barnes; S B Kapadia
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

4.  High-resolution whole-genome analysis of skull base chordomas implicates FHIT loss in chordoma pathogenesis.

Authors:  Roberto Jose Diaz; Mustafa Guduk; Rocco Romagnuolo; Christian A Smith; Paul Northcott; David Shih; Fitim Berisha; Adrienne Flanagan; David G Munoz; Michael D Cusimano; M Necmettin Pamir; James T Rutka
Journal:  Neoplasia       Date:  2012-09       Impact factor: 5.715

5.  Lineage-restricted clonality in biphasic solid tumors.

Authors:  J A Fletcher; G S Pinkus; N Weidner; C C Morton
Journal:  Am J Pathol       Date:  1991-05       Impact factor: 4.307

6.  Update on the cytogenetics and molecular genetics of chordoma.

Authors:  Lidia Larizza; Pietro Mortini; Paola Riva
Journal:  Hered Cancer Clin Pract       Date:  2005-02-15       Impact factor: 2.857

7.  Solitary lymph node metastasis without local recurrence of primary chordoma.

Authors:  J Sopta; G Tulic; V Mijucic; P Mamontov; N Mandic
Journal:  Eur Spine J       Date:  2008-10-23       Impact factor: 3.134

8.  Chordomas: pathological features; ploidy and silver nucleolar organizing region analysis. A study of 36 cases.

Authors:  K E Schoedel; A J Martinez; T M Mahoney; L Contis; M J Becich
Journal:  Acta Neuropathol       Date:  1995       Impact factor: 17.088

9.  Cervical chondroid chordoma in a standard dachshund: a case report.

Authors:  Øyvind Stigen; Nina Ottesen; Hans Gamlem; Caroline P Åkesson
Journal:  Acta Vet Scand       Date:  2011-10-21       Impact factor: 1.695

Review 10.  Immunophenotypic features of dedifferentiated skull base chordoma: An insight into the intratumoural heterogeneity.

Authors:  Kelvin Manuel Piña Batista; Kenia Yoelvi Alvarez Reyes; Fátima Pérez Lopez; Andrés Coca Pelaz; Ivan Fernandez Vega; José Luis Llorente Pendás; Antonio Saiz Ayala; Aurora Astudillo; Jorge Andrés Nuñez Rojas; Patricia Barrio Fernandez
Journal:  Contemp Oncol (Pozn)       Date:  2017-12-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.